PR Newswire Clinical TrialsOriginal article
Marengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion
PartnershipTriSTAR programPositive
AI Analysis
Summary
Marengo nominates its first drug candidate from the strategic TriSTAR collaboration with Ipsen as it advances into IND-enabling development. The company also appointed Saso Cemerski as Senior Vice President, Head of Immunology, to lead pipeline expansion in precision T-cell engagement.
Outcome Details
First drug candidate nominated under TriSTAR collaboration advancing into IND-enabling development
Importance:6/10
Sentiment:
0.65
partnershipTriSTAR collaborationT-cell engagerIND-enabling developmentpipeline expansionmanagement appointment
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 4, 2026 11:00 AM